 |
|
|
|
 |
||||||||||||||||||||||||||||||||||||||||||||
Cipher receives Patent Notice of Allowance for CIP-ISOTRETINOIN09 Jun 2008 - Cipher Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-ISOTRETINOIN, the Company's novel formulation of the acne medication isotretinoin. The required issue and publication fees will now be paid so that the patent can be issued. The patent includes claims related to the reduced food effect of CIP-ISOTRETIOIN relative to currently marketed formulations."Having the U.S. patent allowed represents an important milestone on our path to commercialization for CIP-ISOTRETINOIN," said Larry Andrews, President & CEO of Cipher. "It also reinforces that the product is truly differentiated from currently marketed formulations." Additional information
News regarding Technology |
|
|||||||||||||||||||||||||||||||||||||||||||||||
| Product of the Week |
||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
 Top |
|||
Contact
Print version
PDF version
Send article
RSS feed
